A5044186393- Sarcoma Diagnosis and Treatment
- Cancer-related gene regulation
- Genomics and Chromatin Dynamics
- Ubiquitin and proteasome pathways
- RNA modifications and cancer
- Cancer Cells and Metastasis
- RNA Research and Splicing
- Inflammatory mediators and NSAID effects
- Immune Response and Inflammation
- Cancer Immunotherapy and Biomarkers
- Fatty Acid Research and Health
- Chromatin Remodeling and Cancer
- Cancer Genomics and Diagnostics
German Cancer Research Center
2022-2024
Heidelberg University
2022-2024
Hopp Children's Cancer Center Heidelberg
2022-2024
Huntsman Cancer Institute
2024
Children's Cancer Center
2024
University of Utah
2024
University of Crete
2018-2020
Background Toll-like receptors (TLRs) play essential role in innate and acquired immunity, are expressed various cell types, associated with altered susceptibility to many diseases, cancers. The aim of this study was investigate TLR2 (-196 to-174del), TLR4 (Asp299Gly Thr399Ile) TLR9 (T1237C T1486C) gene polymorphisms at risk colorectal cancer (CRC) development progression. Methods Peripheral blood obtained from 397 patients adjuvant (stage II/III, n = 202) metastatic (n 195) CRC. Moreover,...
The current study aimed at the optimization of circulating tumor cell (CTC) enrichment for downstream protein expression analyses in non-small lung cancer (NSCLC) to serve as a tool investigation immune checkpoints real time. Different approaches—ficoll density, erythrolysis, their combination with magnetic separation, ISET, and Parsortix—were compared spiking experiments using A549, H1975, SKMES-1 NSCLC lines. most efficient methods were tested patients (n = 15) receiving immunotherapy...
Abstract The SS18-SSX fusion drives oncogenic transformation in synovial sarcoma by bridging SS18, a member of the mSWI/SNF (BAF) complex, to Polycomb repressive complex 1 (PRC1) target genes. Here we show that ability occupy H2AK119ub1-rich regions is an intrinsic property its SSX C terminus, which can be exploited transcriptional regulators beyond SS18. Accordingly, recruitment occurs manner independent core components and catalytic activity BAF. Alternative fusions are also recruited...
Summary Synovial sarcoma (SyS) is an aggressive soft-tissue malignancy characterized by a pathognomonic chromosomal translocation leading to the formation of SS18::SSX fusion oncoprotein. associates with mammalian BAF complexes suggesting deregulation chromatin architecture as oncogenic driver in this tumour type. To examine epigenomic state SyS we performed comprehensive multi-omics analysis on 52 primary pre-treatment human tumours. Our revealed continuum states across cohort at target...
<title>Abstract</title> Synovial Sarcoma (SS) is driven by the SS18::SSX fusion oncoprotein and ultimately refractory to therapeutic approaches. alters ATP-dependent chromatin remodeling BAF (mammalian SWI/SNF) complexes, leading degradation of canonical (cBAF) complex amplified presence an SS18::SSX-containing non-canonical (ncBAF or GBAF) that drives SS-specific transcription program tumorigenesis. We demonstrate activates SUMOylation SSs are sensitive small molecule SAE1/2 inhibitor,...
Abstract Synovial Sarcoma (SS) is driven by the SS18::SSX fusion oncoprotein. and ultimately refractory to therapeutic approaches. alters ATP-dependent chromatin remodeling BAF (mammalian SWI/SNF) complexes, leading degradation of canonical (cBAF) complex amplified presence an SS18::SSX-containing non-canonical (ncBAF or GBAF) that drives SS-specific transcription program tumorigenesis. We demonstrate activates SUMOylation SSs are sensitive small molecule SAE1/2 inhibitor, TAK-981....
ABSTRACT The SS18-SSX fusion drives oncogenic transformation in synovial sarcoma by bridging SS18, a member of mSWI/SNF complex, to Polycomb repressive complex 1 (PRC1) target genes. Here we show that the SSX C-terminus, via its SSXRD domain, directs chromatin binding independently SS18. specific targeting is mediated interaction with mono ubiquitinated H2A (H2AK119ub1) and histone MacroH2A which overlaps genome wide. Variant Repressive Complex 1.1 (PRC1.1) acts as main depositor H2AK119ub1...